Deeplex® Myc-TB

Deeplex® Myc-TB

Innovative Diagnostic Solution for Tuberculosis Drug Resistance

Powered by GenoScreen

Get a free tailored demonstration based on your needs

deeplex_CE_48ech_5tubes_sans_fond

THE ALL-IN-ONE SOLUTION FOR EXTENSIVE DETECTION OF MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE

Deeplex® Myc-TB, developed by GenoScreen, is an innovative and integrated culture-free diagnostic kit, providing molecular results on resistance or susceptibility to 15 anti-TB drugs in less than 48 hours. The assay is based on targeted deep sequencing and automated data analysis via the secure Deeplex® Myc-TB web application.

 

Deeplex® Myc-TB can detect tuberculosis heteroresistance down to 1-3%, and also identifies M. tuberculosis complex (sub)lineages and spoligotypes as well as more than 100 species of non-tuberculous mycobacteria (NTM).

 

By providing rapid and extensive prediction of genetic resistance to anti-TB drugs, this innovative test represents a powerful  tool for guiding effective therapeutic management of patients suffering from tuberculosis.

15

anti-TB drugs screened

48h

from clinical samples to results

1-3%

heteroresistance detection
sensitivity

>100

mycobacterial species identified

DEEPLEX® MYC-TB INCLUDES

  • A Deeplex® Master Mix: a single 24-plex PCR mix for culture-free amplification of 18 M. tuberculosis drug resistance-associated gene targets combined with targets for mycobacterial species identification and MTBC strain genotyping.
  • An internal control for in-sample quality control,
  • A positive control for test validation,
  • An activation code to access the Deeplex® Myc-TB web application.

TUBERCULOSIS, A GLOBAL PUBLIC HEALTH CHALLENGE

Tuberculosis (TB) is amongst the most lethal infectious diseases globally, with  10 million new cases annually, causing near 1.5 million deaths each year.

 

This contagious disease most often develops in the lungs, but can also affect multiple other parts of the body. It is caused by bacteria part of the Mycobacterium tuberculosis complex (MTBC).

 

Treatment of active TB requires the uptake of combination of multiple antibiotics for 6 months or more.

 

DRUG-RESISTANT TB, A RISING THREAT

The World Health Organization (WHO) estimated that about 450,000 new cases of multi-drug resistant (MDR) or rifampicin-resistant TB occurred in 2021, of which ~6% were extensively drug resistant TB (XDR-TB, additional resistance to at least one additional Group A drug).

If the MTBC strain that infects the patient is resistant to the drugs part of the treatment regimen, the therapy will be unsuccessful. Drug resistance can also amplify when pre-existing resistance is undetected.

Therefore, rapid, accurate and extensive detection of drug susceptibility and drug resistance is crucial for effective patient treatment, and to prevent further development of drug resistance and transmission of TB.

DOWNLOAD THE TECHNICAL NOTE

Scroll to Top